0001845459 false 0001845459 2023-10-24 2023-10-24 0001845459 us-gaap:CommonStockMember 2023-10-24 2023-10-24 0001845459 us-gaap:WarrantMember 2023-10-24 2023-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 24, 2023

 

 

NKGen Biotech, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-40427   86-2191918
(State of
incorporation)		   (Commission
File No.)		   (IRS Employer
Identification No.)

  

3001 Daimler St.

Santa Ana, California 92705

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (949) 396-6830

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each
exchange
on which registered

Common Stock, $0.0001 par value per share   NKGN   Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share   NKGNW   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 8.01 Other Events.

 

On October 24, 2023, NKGen Biotech, Inc. announced that the U.S. Food and Drug Administration cleared its investigational new drug application for SNK01 natural killer cell therapy for treatment of moderate Alzheimer’s Disease.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 24, 2023 NKGEN BIOTECH, INC.
     
  By: /s/ Paul Y. Song
    Paul Y. Song
    Chief Executive Officer

 

 

v3.23.3
Cover
Oct. 24, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 24, 2023
Entity File Number 001-40427
Entity Registrant Name NKGen Biotech, Inc.
Entity Central Index Key 0001845459
Entity Tax Identification Number 86-2191918
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3001 Daimler St.
Entity Address, City or Town Santa Ana
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92705
City Area Code 949
Local Phone Number 396-6830
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol NKGN
Security Exchange Name NASDAQ
Warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol NKGNW
Security Exchange Name NASDAQ
NKGen Biotech (NASDAQ:NKGN)
Historical Stock Chart
Von Okt 2024 bis Nov 2024 Click Here for more NKGen Biotech Charts.
NKGen Biotech (NASDAQ:NKGN)
Historical Stock Chart
Von Nov 2023 bis Nov 2024 Click Here for more NKGen Biotech Charts.